Shares in Santen Pharmaceutical (OTC:SNPHY) fell -3% today after the company’s U.S. subsidiary said that the FDA rejected the application for its intravitreal sirolimus therapy
The company is developing its DE-109 product to treat people with noninfectious uveitis of the posterior segment, which can cause blindness in adults.
Get the full story at our sister site, Drug Delivery Business News.